Single and multiple ascending doses of AZD1981 in Japan - JSAD/JMAD
Study identifier:D9831C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomised, Placebo-Controlled, Double-Blind, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of AZD1981 in Healthy Male Japanese and Caucasian Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD1981, Placebo
Sex
Male
Actual Enrollment
47
Study type
Interventional
Age
20 Years - 45 Years
Date
Study Start Date: 01 Aug 2008
Primary Completion Date: 01 Oct 2008
Study Completion Date: 01 Oct 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD1981 Oral tablet, 250 mg single dose |
| Experimental: 2 | Drug: AZD1981 Suspension, 15, 75, 1000 and 2000 mg |
| Placebo Comparator: 3 | - |
Contacts
Investigators
Principal Investigator
Elizabeth Hancox
Europe Chiltern International Ltd, Berkshire, UK
